Kenji Hayashihara
Overview
Explore the profile of Kenji Hayashihara including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
256
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Okuma Y, Kubota K, Shimokawa M, Hashimoto K, Kawashima Y, Sakamoto T, et al.
JAMA Oncol
. 2023 Nov;
10(1):43-51.
PMID: 37991747
Importance: Non-small cell lung cancer (NSCLC) with uncommon EGFR mutations is a rare subgroup, composing 14% of all EGFR mutations. Objective: To determine the usefulness of osimertinib in previously untreated...
2.
Yabuuchi Y, Minami Y, Kuroda A, Ooba N, Matsuda T, Kanazawa J, et al.
Intern Med
. 2023 Nov;
63(12):1801-1806.
PMID: 37952958
Cold agglutinin disease is a subtype of autoimmune hemolytic anemia that occurs via the activation of specific anti-red blood cell antibodies (agglutinins) at low temperatures. Autoimmune hemolytic anemia has been...
3.
Yabuuchi Y, Hiroshima K, Oshima H, Kanazawa J, Hayashihara K, Nakagawa T, et al.
Oncol Lett
. 2022 Nov;
24(6):440.
PMID: 36420072
Mesothelioma (MIS) is defined as a preinvasive mesothelioma that forms a single layer of mild atypical mesothelial cells lining on the serosa surface of pleura. The atypical mesothelial cells present...
4.
Yabuuchi Y, Saito T, Hirano H, Nonaka M, Arai N, Hyodo K, et al.
Respir Res
. 2022 Nov;
23(1):295.
PMID: 36316747
Background: Pleuroparenchymal fibroelastosis (PPFE) is a rare fibrosing lung disease with a predilection for the upper lobe and its progression causes hypoventilation, resulting in hypercapnia. Even though the association between...
5.
Terai H, Soejima K, Shimokawa A, Horinouchi H, Shimizu J, Hase T, et al.
JTO Clin Res Rep
. 2022 Oct;
3(11):100404.
PMID: 36275911
Introduction: Pembrolizumab is a programmed death-ligand 1 inhibitor that was initially indicated for monotherapy in patients with advanced lung cancer. The Japanese Lung Cancer Society conducted an observational study on...
6.
Yabuuchi Y, Nakagawa T, Shimanouchi M, Usui S, Hayashihara K, Oh-Ishi S, et al.
Case Rep Oncol
. 2021 Jan;
13(3):1357-1363.
PMID: 33442355
Recurrence of oestrogen receptor (ER)-positive breast cancer rarely occurs postoperatively after a long period. Breast cancer cells survive and settle in distant organs in a dormant state, a phenomenon known...
7.
Yamada Y, Tamura T, Yamamoto Y, Ichimura H, Hayashihara K, Saito T, et al.
Anticancer Res
. 2020 Sep;
40(10):5757-5764.
PMID: 32988903
Background/aim: To describe real clinical outcomes in patients with non-small cell lung cancer who have uncommon epidermal growth factor receptor (EGFR) mutations. Materials And Methods: We performed a retrospective chart...
8.
Numata T, Endo T, Yanai H, Ota K, Yamamoto Y, Shimizu K, et al.
In Vivo
. 2020 Jul;
34(4):2095-2100.
PMID: 32606188
Aim: To clarify the correlation between serum levels of carcinoembryonic antigen (CEA) and cytokeratin 19 fragment (CYFRA) and metastasis and survival in anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer...
9.
Miyazaki K, Sato S, Kodama T, Numata T, Endo T, Yamamoto Y, et al.
In Vivo
. 2020 Jul;
34(4):2001-2007.
PMID: 32606173
Aim: To clarify the clinicopathological features in elderly anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer (NSCLC) patients. Patients And Methods: A retrospective study was performed in 129 ALK...
10.
Okauchi S, Numata T, Nawa T, Ichimura H, Saito T, Hayashihara K, et al.
Anticancer Res
. 2020 Feb;
40(2):957-964.
PMID: 32014940
Background/aim: To describe real clinical outcomes when using systemic therapy to treat non-small cell lung cancer (NSCLC) patients who have anaplastic lymphoma kinase (ALK) fusion gene mutation. Patients And Methods:...